SAN FRANCISCO and BERLIN--(BUSINESS WIRE)--Jun 11, 2024-- Mahana Therapeutics, a leading provider of prescription and wellness digital therapeutics, announced today that it has completed price negotiations with Germany’s National Association of Statutory Health Insurance Funds (GKV-SV). The GKV-SV, assigned by the German health insurance funds, is responsible for establishing the permanent price of digital therapeutics following their permanent listing on the DiGA-directory, the official BfArM (germ.: Bundesinstitut für Arzneimittel und Medizinprodukte, engl.
: Federal Institute for Pharmaceuticals and Medical Devices) register for all approved DiGAs (Digital Health Applications, or “Digitale Gesundheitsanwendungen”). Cara Care for IBS has been permanently reimbursed since November 2023 by all statutory health insurers in Germany, making it widely accessible to all irritable bowel syndrome (IBS) patients. This press release features multimedia.
View the full release here: https://www.businesswire.com/news/home/20240610971833/en/ Cara Care for IBS can be prescribed and re-prescribed for 90 days and is approved for patients aged 18 to 70.
Cara Care for IBS complements medical guidelines and can be used in combination with standard of care therapies or as a stand-alone therapeutic option. (Photo: Business Wire) The process of establishing the GKV-SV permanent price was based on a comprehensive, value-based evaluation of Cara Care for IBS . This evaluation included assessi.
